Mecbotamab Biosimilar – Anti-AXL mAb – Research Grade from ProteoGenix; catalogue PX-TA1864; research use only.
Know who made it. See the evidence. Buy through one marketplace.
cancer therapies has revolutionized the treatment of various types of cancer. Monoclonal antibodies (mAbs) have emerged as a promising class of therapeutics for targeted cancer therapy due to their high specificity and low toxicity. Mecbotamab biosimilar, also known as anti-AXL mAb, is a novel monoclonal antibody that is being investigated for its potential in cancer treatment. In this article, we will explore the structure, activity, and potential applications of Mecbotamab biosimilar in the field of cancer research.
Mecbotamab biosimilar is a fully humanized IgG1 monoclonal antibody that specifically targets the AXL receptor tyrosine kinase. It is produced using recombinant DNA technology, where the variable regions of the antibody are derived from human cells and fused with constant regions of mouse antibodies. This process results in a chimeric antibody that has both human and mouse components, making it less immunogenic and more suitable for therapeutic use in humans.
The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The variable domains of Mecbotamab biosimilar are responsible for its high specificity and binding affinity towards the AXL receptor.
The AXL receptor is a member of the TAM (TYRO3, AXL, and MERTK) family of receptor tyrosine kinases, which play a crucial role in cell survival, proliferation, and migration. AXL is overexpressed in various types of cancer, including breast, lung, and pancreatic cancer, and is associated with tumor growth, metastasis, and resistance to chemotherapy. Mecbotamab biosimilar binds to the AXL receptor and blocks its activity, leading to inhibition of cancer cell growth and survival.
cancer cells. It can induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), where immune cells are recruited to kill cancer cells that are tagged with the antibody. This mechanism of action makes Mecbotamab biosimilar a potential immunotherapy for cancer treatment.
Mecbotamab biosimilar is currently being evaluated in preclinical and clinical studies for its potential in cancer treatment. In preclinical studies, it has shown promising results in inhibiting tumor growth and metastasis in various cancer models. In a phase 1 clinical trial, Mecbotamab biosimilar was well-tolerated and showed preliminary signs of efficacy in patients with advanced solid tumors, including breast, lung, and ovarian cancer.
Additionally, Mecbotamab biosimilar has the potential to be used in combination with other cancer therapies. It has shown synergistic effects when combined with chemotherapy, radiotherapy, and other targeted therapies. This makes it a promising candidate for combination therapy in the treatment of cancer.
In summary, Mecbotamab biosimilar is a novel monoclonal antibody that specifically targets the AXL receptor and has shown promising results in preclinical and clinical studies for its potential in cancer treatment. Its unique structure and mechanism of action make it a promising candidate for targeted cancer therapy, and further studies are needed to fully explore its potential in the field of cancer research.
Keywords: Mecbotamab biosimilar, anti-AXL mAb, monoclonal antibody, cancer therapy
ProteoGenix catalogue number PX-TA1864. For research use only.
Target: Mecbotamab Biosimilar – Anti-AXL mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Mecbotamab Biosimilar – Anti-AXL mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
